Brooks Patrick Terrence, Minculescu Lia, Svanberg Teglgaard Rebecca, Hartling Hans Jakob, Salado-Jimena Jose Antonio, Friis Lone Smidstrup, Kornblit Brian, Schjødt Ida, Petersen Søren Lykke, Andersen Niels Smedegaard, Nielsen Susanne Dam, Lundgren Jens, Marquart Hanne Vibeke, Gjaerde Lars Klingen, Sengeløv Henrik, Ostrowski Sisse Rye
Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.
Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Sci Rep. 2025 Jul 1;15(1):21029. doi: 10.1038/s41598-025-06718-y.
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a treatment modality for several hematological and immune-driven diseases. A conditioning regimen precedes transplantation. These comprise myeloablative (MA) conditioning consisting of chemotherapeutics often in combination with high-dose total body irradiation (TBI), while non-myeloablative (NMA) conditioning regimens use reduced dosage of chemotherapy and TBI allowing allo-HCT to patients who would otherwise not be eligible for treatment. While cellular immune reconstitution in allo-HCT patients has been well studied, differences between MA and NMA conditioned patients including the functional status of the immune system post-transplantation remains unclear. Seventy-seven patients undergoing allo-HCT were included in the main study, only including patients receiving peripheral blood stem cell grafts, no ATG treatment and no other GVHD prophylaxis than tacrolimus + methotrexate or cyclosporine + MMF + sirolimus (median age 59; IQR: 48-65). The cohort consisted of 34 patients receiving MA conditioning and 43 NMA conditioned patients. As a proxy for post-transplantation immune function, we analyzed stimulated cytokine release patterns in whole-blood samples from MA and NMA patients before and after transplantation alongside major immune cell phenotypes and T cell chimerism on day 28 after transplantation. Notably, among patients receiving grafts from peripheral blood apheresis, MA patients exhibited higher T cell counts, and elevated CD3/CD28-stimulated cytokine release compared to NMA patients. Assessment of associations between cytokine release and immune cell concentration associations indicated that variation in T cell or other immune cell concentrations between the cohorts could not account for differences in CD3/CD28-stimulated cytokine release. Meanwhile, LPS- and R848-stimulated cytokine release was associated with innate immune cell subtypes. A secondary study amongst MA conditioned patients further revealed that those who received fludarabine and treosulfan (n = 35) had higher T cell concentration and stimulated immune function compared to patients receiving more intense MA regimens (n = 15). These findings highlight the complex impact conditioning has on immune function after allo-HCT. Further analyses of T cell compartments and myeloid/lymphoid innate cells are needed to further understand the functional differences observed between conditioning groups and the potential impact on clinical outcomes.
异基因造血干细胞移植(allo-HCT)是治疗多种血液系统疾病和免疫相关疾病的一种治疗方式。移植前需进行预处理方案。这些方案包括清髓性(MA)预处理,通常由化疗药物联合大剂量全身照射(TBI)组成,而非清髓性(NMA)预处理方案使用剂量降低的化疗和TBI,使allo-HCT能够应用于那些原本不符合治疗条件的患者。虽然对allo-HCT患者的细胞免疫重建已进行了充分研究,但MA和NMA预处理患者之间的差异,包括移植后免疫系统的功能状态仍不清楚。主要研究纳入了77例接受allo-HCT的患者,仅包括接受外周血干细胞移植、未接受抗胸腺细胞球蛋白(ATG)治疗且除他克莫司+甲氨蝶呤或环孢素+霉酚酸酯+西罗莫司外未接受其他移植物抗宿主病(GVHD)预防措施的患者(中位年龄59岁;四分位间距:48 - 65岁)。该队列包括34例接受MA预处理的患者和43例接受NMA预处理的患者。作为移植后免疫功能的替代指标,我们分析了MA和NMA患者移植前后全血样本中刺激后的细胞因子释放模式,以及移植后第28天的主要免疫细胞表型和T细胞嵌合情况。值得注意的是,在接受外周血单采移植的患者中,MA患者的T细胞计数更高,且与NMA患者相比,CD3/CD28刺激后的细胞因子释放升高。对细胞因子释放与免疫细胞浓度关联的评估表明,队列间T细胞或其他免疫细胞浓度的差异无法解释CD3/CD28刺激后的细胞因子释放差异。同时,脂多糖(LPS)和R848刺激后的细胞因子释放与固有免疫细胞亚型相关。对MA预处理患者的一项二次研究进一步显示,与接受更强化MA方案的患者(n = 15)相比,接受氟达拉滨和曲奥舒凡的患者(n = 35)T细胞浓度更高且免疫功能受刺激更强。这些发现突出了预处理对allo-HCT后免疫功能的复杂影响。需要进一步分析T细胞亚群以及髓系/淋巴系固有细胞,以进一步了解预处理组之间观察到的功能差异以及对临床结局的潜在影响。